Find therapies in clinical trials near you – page 15

ctDNA‑guided Study of Enfortumab Vedotin plus Pembrolizumab in Untreated Patients with Advanced Urothelial Carcinoma

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Efficacy of Enfortumab Vedotin plus Pembrolizumab in Adult Patients with Muscle‑Invasive Bladder Cancer Using a Bladder‑Sparing Response‑Adapted Approach

Pharmacokinetic study of pembrolizumab and drug combination in patients with non‑small cell lung cancer or head and neck squamous cell carcinoma

Pharmacokinetic study of pembrolizumab and drug combination in patients with non‑small cell lung cancer or head and neck squamous cell carcinoma

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

Study of ivonescimab plus enfortumab vedotin versus pembrolizumab plus enfortumab vedotin in previously untreated locally advanced or metastatic urothelial carcinoma

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

A Phase 3 Study of GSK5733584 with drug combination in patients with platinum‑resistant ovarian cancer

Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies

Study of ribociclib with drug combination in early breast cancer patients to test de‑escalated treatment strategies

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Comparison of nivolumab drug combination versus immunotherapy‑TKI sequence in patients with metastatic renal cell carcinoma

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Phase Ib/II study of momelotinib with nivolumab or pembrolizumab in unresectable stage III/IV cutaneous melanoma

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Carboplatin drug combination as neoadjuvant therapy for early stage II triple‑negative breast cancer

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Immune Modulation Study of Rilvegostomig and Pembrolizumab in Patients with Advanced Gastric Cancer

Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

Molecularly Tailored Therapy Versus Standard Care in Patients With Advanced Pancreatic Cancer Using Olaparib, Erlotinib, Crizotinib, Trametinib, Pemigatinib, Selpercatinib, Axitinib, Vismodegib, Pembrolizumab, Larotrectinib, Dabrafenib, Capecitabine, Oxaliplatin, Fluorouracil, Irinotecan, Gemcitabine, Paclitaxel Albumin-Bound, and Calcium Folinate

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer

Morning Versus Afternoon Pembrolizumab, Carboplatin, and Pemetrexed in Adults With Stage IV Non-Squamous Non-Small Cell Lung Cancer